At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 90 enrolled
Drug / intervention
JNJ-77242113 +1 moredrug
Likely dose
JNJ-77242113 administered orally as delayed release tablets (specific dose not stated)AI-extracted
Key inclusion· 5
- ✓Diagnosis of plaque psoriasis (with or without psoriatic arthritis) for at least 26 weeks before first study drug dose
- ✓Body Surface Area (BSA) ≥10% at screening and baseline
- ✓PASI score ≥12 at screening and baseline
- ✓IGA score ≥3 at screening and baseline
Key exclusion· 5
- ✕Non-plaque forms of psoriasis (erythrodermic, guttate, pustular)
- ✕Drug-induced psoriasis from agents such as beta blockers, calcium channel blockers, or lithium
- ✕Prior receipt of IL-23-targeted agents (guselkumab, tildrakizumab, risankizumab)
- ✕Prior IL-17, IL-17R, IL-12/23, or TNF-targeted biologics within 12 weeks or 5 half-lives (whichever is longer)
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2a Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Oral Tablet Formulation of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis
In Brief
A Phase 2 clinical trial evaluating JNJ-77242113 and Placebo for Plaque Psoriasis. Completed, enrolled 90 participants across 34 sites in 6 countries.
Detailed Summary
The purpose of the study is to evaluate the efficacy of an oral tablet formulation of JNJ-77242113 compared with placebo in participants with moderate-to-severe plaque psoriasis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPlaque Psoriasis
CountriesCanada, France, Germany, Poland, Spain, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2023202420252026
First PostedMay 2022
Enrollment StartJun 2022
Primary CompletionMar 2023
Study CompletionApr 2023
TodayJul 2026
First PostedMay 3, 2022
Enrollment StartJun 13, 2022
Primary CompletionMar 23, 2023
Study CompletionApr 10, 2023
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 4.2 years ago
Interventions
JNJ-77242113drug
JNJ-77242113 will be administered orally as delayed release tablets.
Placebodrug
Matching placebo will be administered orally as delayed release tablets.